Skip to main content
. 2018 Oct 31;9:951. doi: 10.3389/fphar.2018.00951

Table 7.

Analysis of secondary outcome: TDW Re-epithelialization.

26–50% 51–75% 76–99% 100% Sum
Skin graft re-epithelialization (TDW) (ITT, n=76 documented cases)
EPO - no. (%) 4 (10%) 7 (17%) 17 (43%) 12 (30%) 40
Placebo - no. (%) 2 (6%) 4 (11%) 13 (36%) 17 (47%) 36
Sum - no. (%) 6 (8%) 11 (14%) 30 (40%) 29 (38%) 76

ITT population data are presented as absolute numbers and in %.